PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis.

Zhe Wang,Ruolei Li,Niuniu Hou,Juliang Zhang,Ting Wang,Pengyu Fan,Cheng Ji,Bo Zhang,Liuyin Liu,Yaping Wang,Jing Kong,Qing Yao, Jie Duan,Ge Zhao,Rui Ling,Jian Zhang

Journal for immunotherapy of cancer（2023）

引用 0|浏览5

暂无评分

摘要

Our results reveal that the activation of PRMT5 can modulate iron metabolism and drive resistance to ferroptosis inducers and immunotherapy. Accordingly, PRMT5 can be used as a target to change the immune resistance of TNBC.

查看译文

关键词

prmt5,breast cancer,immunotherapy efficacy,triple-negative

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要